Biomind Labs Inc.
BMNDF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $1 | $1 |
| G&A Expenses | $0 | $1 | $2 | $3 |
| SG&A Expenses | $0 | $1 | $2 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $1 | $3 | $3 |
| Operating Income | -$0 | -$1 | -$3 | -$3 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | -$0 | -$0 | -$1 |
| Pre-Tax Income | -$0 | -$1 | -$3 | -$4 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$1 | -$3 | -$4 |
| % Margin | – | – | – | – |
| EPS | -0.003 | -0.016 | -0.04 | -0.06 |
| % Growth | 79% | 59.4% | 33.5% | – |
| EPS Diluted | -0.003 | -0.016 | -0.04 | -0.06 |
| Weighted Avg Shares Out | 76 | 75 | 75 | 72 |
| Weighted Avg Shares Out Dil | 76 | 75 | 75 | 72 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$1 | -$3 | -$3 |
| % Margin | – | – | – | – |